EVIDENCE. COMPARISONS. CLEAR NEXT STEPS.FOR US CLINIC TEAMS PROCUREMENT RESEARCH
Expert Q&A

2. Can clinics still prescribe compounded semaglutide or tirzepatide after the shortage—and what would justify this particular preparation?

Dose Diligence research deskSection 06 · Page 5 of 22Last updated 17 Nov 2026

Framing: a prescription, added ingredient or lower price is not automatic clearance. FDA’s April 2026 clarification specifically discusses semaglutide combined with vitamin B12 as potentially remaining an essentially copied product. Its 503A guidance also explains that lower price does not establish the necessary formulation-related significant difference. (fda.gov)

Put to: Jesse Dresser, Tenille Davis and Robert Kushner.
Buyer owner: Medical director and counsel.

Why it matters: The clinic needs a defensible patient-specific assessment, not a standard commercial rationale attached to every prescription.

A good answer should cover:

  • The applicable statutory conditions, FDA guidance and any relevant enforcement policy, clearly distinguished from one another.
  • How the prescriber identifies the change and its significance for the individual patient.
  • Why the proposed preparation is needed rather than an appropriate approved option.
  • Who documents, reviews and retains the reasoning—and what happens when the supplier proposes the wording.
  • The strongest contrary interpretation and the facts that would make counsel reject the arrangement.

Follow-up that tests the answer: “How would you distinguish genuine individual clinical judgement from a platform that requires every prescriber to select the same justification?” FDA’s September 2026 warning letter makes this a concrete diligence issue. (fda.gov)

Evidence to request: A counsel-reviewed assessment process and de-identified examples reviewed under appropriate confidentiality controls. Do not distribute a universal ‘legal wording’ template.

Expert quote — reserved: ________________________________________

Sources cited on this page

  1. fda.gov · Source 1 ↗https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize
  2. fda.gov · Source 2 ↗https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/empower-clinic-services-llc-dba-empower-pharmacy-738238-09182026
Section sources →